Aplastic anemia associated with osimertinib: Analysis of the FDA adverse event reporting system
{{output}}
Objective: Aplastic anemia (AA) is a life-threatening disease, and drug-induced AA is rare. Recently, studies on cases that possibly developed AA following osimertinib treatment have been conducted. This study evaluated the assoc... ...
